Results 51 to 60 of about 19,748 (246)

α-Diaminobutyric acid-linked hairpin polyamides [PDF]

open access: yes, 2007
A hairpin polyamide-chlorambucil conjugate linked by α-diaminobutyric acid (α-DABA) has been shown to have interesting biological properties in cellular and small animal models.
Dervan, Peter B.   +2 more
core   +3 more sources

Clinical management and outcomes for 51 Pugs reportedly diagnosed with protein‐losing enteropathy using VetCompass primary care veterinary data

open access: yesJournal of Small Animal Practice, EarlyView.
Objectives To report the clinicopathological findings, treatment and outcomes of Pugs diagnosed with protein‐losing enteropathy using VetCompass primary care clinical data in the UK and to determine if referral or any specific treatments for protein‐losing enteropathy were associated with outcome. Materials and Methods Retrospective VetCompass study of
A. Kathrani   +3 more
wiley   +1 more source

B‐Cell Chronic Lymphocytic Leukemia in a Cat

open access: yesVeterinary Clinical Pathology, EarlyView.
ABSTRACT Background An 8.8‐year‐old male neutered Persian cat was presented with a history of recent intermittent mild lethargy, hyporexia, and weight loss. Physical examination revealed pale mucous membranes, an enlarged right mandibular lymph node, and organomegaly suspected to be an enlarged spleen.
James Andre Mori   +3 more
wiley   +1 more source

Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study [PDF]

open access: yes, 2015
Purpose: To describe the health-related quality of life (HRQoL) of an unselected population of patients with chronic lymphocytic leukaemia (CLL) including untreated patients. Methods: HRQoL was measured by the EORTC QLQ-C30 including the CLL16 module, EQ-
Daenen, S.M.G.J. (Simon)   +15 more
core   +1 more source

Disease progression more than 6 years after treatment impacts overall survival in mantle cell lymphoma

open access: yesInternational Journal of Cancer, Volume 158, Issue 7, Page 1836-1845, 1 April 2026.
What's new? Patients with mantle cell lymphoma showing disease progression within 24 months of primary treatment have worse prognosis than patients with later progression. This population‐based study suggests that although early relapse is especially serious, disease progression more than 6 years after treatment still leads to worse survival than the ...
Sara Ekberg   +5 more
wiley   +1 more source

Chemical genetics analysis of an aniline mustard anticancer agent reveals complex I of the electron transport chain as a target [PDF]

open access: yes, 2011
Supplementary information is available at the Journal of Biological Chemistry website.The antitumor agent 11β (CAS 865070-37-7), consisting of a DNA-damaging aniline mustard linked to an androgen receptor (AR) ligand, is known to form covalent DNA ...
Cossarizza   +30 more
core   +1 more source

Is Micronucleus Assay a Suitable Biomarker for Evaluating the Cancer Risk in Professionals Exposed to Antineoplastic Drugs? A Systematic Review

open access: yesJournal of Applied Toxicology, Volume 46, Issue 3, Page 733-753, March 2026.
ABSTRACT The widespread use of antineoplastic drugs in cancer treatment has led to significant concerns regarding the potential health risks posed to healthcare professionals involved in the preparation, administration, and handling of these chemical compounds, including genotoxicity.
Thiago Guedes Pinto   +6 more
wiley   +1 more source

Chronic Lymphocytic Leukemia in Elderly Patients: Own Experience

open access: yesЛьвівський клінічний вісник, 2017
Introduction. The annual incidence rate of chronic lymphocytic leukemia (CLL) in Europe is 1­4 per 100 000 population. The disease is more common in older patients.
Vyhovska O.   +7 more
doaj   +1 more source

Differential interactions of Falcarinol combined with anti-tumour agents on cellular proliferation and apoptosis in human lymphoid leukaemia cell lines [PDF]

open access: yes, 2015
Leukaemia is the most common childhood cancer, and whilst recent advances in therapy have improved survival, current treatments are still limited by their side effects.
Cross, Neil   +3 more
core   +1 more source

Home - About - Disclaimer - Privacy